BlueLinx Holdings
BXC
71.39
+0.43
+0.61%
BlueLinx Holdings
US · BXC
#3676 by market cap
71.39
+0.43
+0.61%
Live - 5344 symbols - heartbeat 241s ago
· 2026-10-08 10:04
Pre-market
69.76
-1.69%
After-hours
70.96
0.00%
- Market cap
- 561.14M
- P/E (TTM)i
- -310.39
- P/Bi
- 0.90
- EPSi
- 0.02
- Div yieldi
- 0.00%
- 52W posi
- 54%
Reader sentiment
Are you bullish or bearish on BXC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.41, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +0.05% YoY
Margins
- Gross margin
- 15.29%
- Operating margin
- 1.10%
- Net margin
- 0.01%
Key ratios & quality
- Enterprise valuei
- 503.27M
- Altman Z-Scorei
- 3.41
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.86B | 2.64B | 3.10B | 4.28B | 4.45B | 3.14B | 2.95B | 2.95B |
| Gross profit | 331.85M | 356.92M | 477.73M | 778.43M | 832.98M | 527.02M | 489.14M | 451.63M |
| Selling & admin expenses | 319.31M | 291.53M | 314.23M | 322.21M | 366.31M | 355.82M | 365.53M | 381.11M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | -13.29M | 22.07M | 131.71M | 429.65M | 438.94M | 138.45M | 87.30M | 32.48M |
| Pretax profit | -60.21M | -21.61M | 95.08M | 393.88M | 394.76M | 81.89M | 70.69M | 129.00K |
| Tax | -12.15M | -3.95M | 14.20M | 97.74M | 98.59M | 33.35M | 17.57M | -90.00K |
| Net profit | -48.05M | -17.66M | 80.88M | 296.13M | 296.18M | 48.54M | 53.12M | 219.00K |
| Basic EPS | -5 | -2 | 9 | 31 | 32 | 5 | 6 | 0 |
| Diluted EPS | -5.21 | -1.89 | 8.55 | 29.99 | 31.51 | 5.39 | 6.19 | 0.02 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 709.23M | 780.11M | 748.87M | 715.80M | 731.15M | 814.08M |
| Gross profit | 111.13M | 119.69M | 108.19M | 112.62M | 116.40M | 139.71M |
| Selling & admin expenses | 94.09M | 95.27M | 89.28M | 102.47M | 96.20M | 107.37M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 10.72M | 15.04M | 9.97M | -3.24M | 7.33M | 20.60M |
| Pretax profit | 4.14M | 6.58M | 1.36M | -11.96M | -1.82M | 11.22M |
| Tax | 1.34M | 2.27M | -292.00K | -3.41M | -361.00K | 4.82M |
| Net profit | 2.81M | 4.31M | 1.66M | -8.55M | -1.46M | 6.41M |
| Basic EPS | 0 | 1 | 0 | -1 | 0 | 1 |
| Diluted EPS | 0.33 | 0.54 | 0.20 | -1.08 | -0.18 | 0.81 |
Balance sheet
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 599.85M | 578.04M | 668.41M | 945.17M | 1.08B | 1.12B | 1.13B | 984.47M |
| Cash & ST investments | 8.94M | 11.64M | 82.00K | 85.20M | 298.94M | 521.74M | 505.62M | 385.84M |
| Inventory | 341.85M | 345.81M | 342.11M | 488.46M | 484.31M | 343.64M | 355.91M | 326.00M |
| Total assets | 959.89M | 971.43M | 1.05B | 1.32B | 1.49B | 1.54B | 1.58B | 1.55B |
| Total current liabilities | 196.77M | 171.12M | 229.03M | 243.79M | 210.68M | 218.56M | 233.72M | 211.28M |
| Short-term debt | 9.29M | 15.98M | 12.92M | 13.01M | 14.52M | 17.46M | 21.02M | 31.32M |
| Long-term debt | 497.94M | 458.44M | 321.27M | 291.27M | 292.42M | 293.74M | 295.06M | 296.66M |
| Total liabilities | 974,552,000.00 | 997,508,000.00 | 989,038,000.00 | 954,205,000.00 | 900,013,000.00 | 903,315,000.00 | 931,276,000.00 | 931,964,000.00 |
| Total equity | -14.66M | -26.08M | 59.09M | 363.25M | 590.03M | 634.29M | 646.44M | 617.32M |
| Retained earnings | -236.22M | -252.59M | -171.71M | 124.43M | 420.60M | 469.14M | 522.26M | 522.47M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 1.17B | 1.10B | 1.10B | 984.47M | 1.04B | 1.06B |
| Cash & ST investments | 449.02M | 386.77M | 429.36M | 385.84M | 319.09M | 318.18M |
| Inventory | 399.56M | 391.48M | 345.88M | 326.00M | 371.68M | 375.26M |
| Total assets | 1.63B | 1.58B | 1.58B | 1.55B | 1.60B | 1.60B |
| Total current liabilities | 280.57M | 242.72M | 239.06M | 211.28M | 267.96M | 264.88M |
| Short-term debt | 23.37M | 25.73M | 28.53M | 31.32M | 29.90M | 30.47M |
| Long-term debt | 295.39M | 295.72M | 296.44M | 296.66M | 296.87M | 297.09M |
| Total liabilities | 997,356,000.00 | 962,723,000.00 | 958,946,000.00 | 931,964,000.00 | 982,542,000.00 | 982,085,000.00 |
| Total equity | 636.11M | 621.31M | 623.02M | 617.32M | 615.55M | 621.48M |
| Retained earnings | 525.06M | 529.37M | 531.03M | 522.47M | 521.02M | 527.42M |
Cash flow
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 41.56M | -10.30M | 55.02M | 145.02M | 400.30M | 306.29M | 85.18M | 59.78M |
| Depreciation & amortization | 25.83M | 30.23M | 28.90M | 28.19M | 27.61M | 32.04M | 38.49M | 39.91M |
| Free cash flow | 38.83M | -15.10M | 51.33M | 130.61M | 364.41M | 278.77M | 45.07M | 32.85M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -3.02M | -211.00K | -271.00K | -5.19M | -76.96M | -47.41M | -48.66M | -40.66M |
| Ending cash balance | 8.94M | 11.64M | 82.00K | 85.20M | 298.94M | 521.74M | 505.62M | 385.84M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | -33.91M | -26.76M | 58.62M | 61.83M | -57.23M | 11.18M |
| Depreciation & amortization | 9.55M | 9.79M | 9.74M | 10.82M | 11.97M | 11.47M |
| Free cash flow | -39.84M | -36.37M | 52.67M | 56.39M | -59.83M | 8.79M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -15.03M | -22.12M | -3.42M | -93.00K | -3.11M | -4.32M |
| Ending cash balance | 449.02M | 386.77M | 429.36M | 385.84M | 319.09M | 318.18M |
Returns & efficiency
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -472.52 | -- | 490.06 | 140.23 | 62.14 | 7.93 | 8.29 | 0.03 |
| ROA %i | -6.61 | -1.83 | 8.01 | 25.04 | 21.10 | 3.21 | 3.41 | 0.01 |
| ROIC %i | -2.05 | -- | 17.99 | 39.22 | 30.05 | 5.48 | 5.34 | 1.53 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | 141.73 | 43.73 |
| EBIT margin %i | -0.45 | 1.24 | 4.60 | 10.27 | 9.82 | 3.37 | 3.05 | 1.10 |
| FCF / sales %i | 1.36 | -- | 1.66 | 3.05 | 8.19 | 8.89 | 1.53 | 1.11 |
| Current ratioi | 3.05 | 3.38 | 2.92 | 3.88 | 5.11 | 5.13 | 4.85 | 4.66 |
| Quick ratioi | 1.10 | 1.20 | 1.28 | 1.74 | 2.61 | 3.43 | 3.13 | 2.86 |
| Debt / assetsi | 67.79 | 73.40 | 61.69 | 46.73 | 41.14 | 40.19 | 40.32 | 43.50 |
| LT debt / equityi | -- | -- | 1,072.36 | 165.91 | 101.42 | 94.68 | 95.16 | 104.11 |
| Interest coveragei | -0.27 | 0.60 | 3.01 | 9.66 | 10.34 | 4.45 | 4.65 | 1.00 |
| Revenue CAGR (3Y) %i | 14.30 | 11.92 | 19.49 | 14.32 | 19.05 | 0.42 | -11.62 | -12.77 |
| Net income CAGR (3Y) %i | -- | -- | 8.69 | -- | -- | -15.65 | -43.60 | -90.96 |
| FCF CAGR (3Y) %i | 0.40 | -- | -- | 49.83 | -- | 75.77 | -29.86 | -55.16 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | 5.96 | 4.46 | 2.20 | 0.03 | -0.65 | -0.31 |
| ROA %i | 2.38 | 1.79 | 0.88 | 0.01 | -0.25 | -0.12 |
| ROIC %i | 4.05 | 3.32 | 2.27 | 1.53 | 1.44 | 1.35 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 2.39 | 2.00 | 1.35 | 1.10 | 0.90 | 1.03 |
| FCF / sales %i | 1.42 | -- | -- | 1.11 | 0.43 | 1.93 |
| Current ratioi | 4.16 | 4.55 | 4.60 | 4.66 | 3.90 | 4.01 |
| Quick ratioi | 2.58 | 2.74 | 2.92 | 2.86 | 2.30 | 2.39 |
| Debt / assetsi | 40.33 | 42.01 | 42.28 | 43.50 | 41.75 | 41.87 |
| LT debt / equityi | 99.88 | 102.97 | 102.78 | 104.11 | 103.54 | 103.13 |
| Interest coveragei | 3.83 | 2.99 | 1.92 | 1.00 | 0.82 | 0.96 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Specialty products is the largest reported line at 69.30% of revenue, across 2 reported segments.
- Structural products follows at 30.70%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Specialty products69.30%
Structural products30.70%
Quote time 2026-10-08 10:04:39 · For reference only, not investment advice and not tailored to your situation.